Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OXTR | P30559 | 5/20 | 0.53 |
| ▸ | AVPR1A | P37288 | 3/20 | 0.49 |
| ▸ | CFTR | P13569 | 5/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | TLR2 | O60603 | 1/20 | 0.34 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4941903 | 0.91 | OXTR (0.56) | OXTRAVPR1ACFTRPOLBTLR2 | |
| SCHEMBL4942161 | 0.83 | OXTR (0.54) | OXTRAVPR1AATMSMN1; SMN2 | |
| SCHEMBL5742340 | 0.80 | OXTR (0.67) | OXTRAVPR1AMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL4949347 | 0.79 | OXTR (0.58) | OXTRAVPR1AATMMEN1KMT2A | |
| SCHEMBL4942676 | 0.79 | OXTR (0.73) | OXTRAVPR1APOLBATMMEN1 | |
| SCHEMBL5759282 | 0.79 | OXTR (0.73) | OXTRAVPR1APOLBATMMEN1 | |
| SCHEMBL4938849 | 0.77 | OXTR (0.59) | OXTRAVPR1AKMT2ASMN1; SMN2 | |
| SCHEMBL7086784 | 0.76 | OXTR (0.74) | OXTRAVPR1AMEN1KMT2A | |
| SCHEMBL4944329 | 0.76 | OXTR (0.73) | OXTRAVPR1APOLBMEN1KMT2A | |
| SCHEMBL4939162 | 0.76 | OXTR (0.73) | OXTRAVPR1APOLBMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030171309-A1 | Pharmaceutically active pyrrolidine derivatives as bax inhibitors | MERCK SERONO SA (CH) | 2003-09-11 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030171309-A1 | Pharmaceutically active pyrrolidine derivatives as bax inhibitors | SUCNR1, PYCR1, GLS | OXTR 189/4885AVPR1A 1456/4885CFTR 899/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.